glp-1 ketosis receptor agonists and next-generation metabolic hormone therapies in chronic kidney disease Ketogenic Diets for Body Weight

Hasegawa, K., Sakamaki, Y., Tamaki, M

Population pharmacokinetic analysis indicated dose-proportional pharmacokinetic profiles for both oral and sc, with body weight being the main factor influencing exposure [58]

People with multiple endocrine neoplasia syndrome type 2 (MEN2) or with a personal or family history of medullary thyroid carcinoma (MTC) should not take liraglutide

Impact of streptozotocin on altering normal glucose homeostasis during insulin testing in diabetic rats compared to normoglycemic rats

While tirzepatide generally produces superior weight loss results compared to semaglutide, its dual mechanism as both a GLP-1 and GIP receptor agonist can amplify gastrointestinal side effects for some individuals